|
CREBBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64424029946986E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.36120004157192E-11 |
| Normal-vs-Stage2 |
1.63570000000224E-06 |
| Normal-vs-Stage3 |
3.60822483003176E-12 |
| Normal-vs-Stage4 |
1.82340031962269E-10 |
| Stage1-vs-Stage2 |
7.592600E-01 |
| Stage1-vs-Stage3 |
1.450760E-01 |
| Stage1-vs-Stage4 |
1.435400E-01 |
| Stage2-vs-Stage3 |
1.995420E-01 |
| Stage2-vs-Stage4 |
2.049400E-01 |
| Stage3-vs-Stage4 |
9.391800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.97681887420731E-13 |
| Normal-vs-AfricanAmerican |
6.827600E-04 |
| Normal-vs-Asian |
3.66210000102285E-08 |
| Caucasian-vs-AfricanAmerican |
2.939000E-01 |
| Caucasian-vs-Asian |
8.807000E-01 |
| AfricanAmerican-vs-Asian |
3.658600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.86450896125734E-13 |
| Normal-vs-Female |
2.60647059491248E-12 |
| Male-vs-Female |
3.723400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.47629727623666E-11 |
| Normal-vs-Age(41-60Yrs) |
5.94659876895776E-11 |
| Normal-vs-Age(61-80Yrs) |
4.22406554179133E-12 |
| Normal-vs-Age(81-100Yrs) |
5.016800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.097200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.843800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.151000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.754800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.864600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.392800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.405100E-04 |
| Classical-VS-Follicular |
2.352000E-02 |
| Classical-VS-Other |
1.925750E-01 |
| Classical-VS-Normal |
4.61509719329456E-11 |
| Tall-VS-Follicular |
1.520180E-01 |
| Tall-VS-Other |
8.498400E-01 |
| Tall-VS-Normal |
1.75439662797316E-11 |
| Follicular-VS-Other |
6.425600E-01 |
| Follicular-VS-Normal |
2.98099989137768E-10 |
| Other-VS-Normal |
1.138360E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.88590262798039E-11 |
| Normal-vs-N1 |
1.07860054221476E-10 |
| N0-vs-N1 |
1.654440E-01 |
|
|
